News 2024-05-16
Porton at CPhI North America again
We've had an exciting few days at CPhI North America. We want to express our sincere gratitude to all the present and potential future partners we've engaged with. Whether you require assistance with API route scouting, chemistry optimization, or the manufacturing of intermediates, RSM, or finished API, our teams are ready to support you from our locations in Cranbury (NJ), Slovenia, or our sites in China.
If you are focused on drug product development, the Porton team is equipped to aid in the development of tablets, capsules, liquids, or sterile products, starting from pre-formulation and DS-DP coprocessing through to GMP manufacturing, including high-potent product capabilities. Additionally, our global reach extends to the development of topical and transdermal patch products. How can Porton help you? Contact us.
|
Small Molecules CDMO |
TIDES CDMO |
Biologics (Antibody & ADCs) CDMO |
|
|
|
Others
More
News 2025-07-31
NMPA Approves Jike Shu (Sebaloxavir Marboxil Tablets) for the Treatment of Uncomplicated Influenza in Adults
Self-developed novel PA endonuclease inhibitor anti-influenza drug Jike Shu (Sebaloxavir Marboxil Tablets) has officially received marketing approval from China's National Medical Products Administration (NMPA) for the treatment of uncomplicated influenza in adults.
News 2025-07-31
Porton and Repare Therapeutics Collaborate on OPRD Publication, Demonstrating Strength in Synthetic Process Development and Optimization
Overcoming the challenge of efficient synthesis of PKMYT1 inhibitor Lunresertib
